Reduces fibrotic response to injury and has been shown to prevent fibrosis when administered prior to insult. This is potentially relevant to a wide range of progressive fibrotic treatments including but not limited to; Lung, skin, GI tract, GU tract, Heart, Peritoneum, Kidney, Liver and Mucosa.
LAMELLASOME™ disrupts or significantly slows the progression of fibrosis. This is relevant for conditions of active fibrosis in the lung as well as other tissues where the pathology is similar. This has been demonstrated in model of Radiotherapy Induced Lung Injury.
Products disrupt the progression of fibrosis, the key pathology of progressive pulmonary fibrosis